Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: Biotime Inc and Asterias Biotherapeutics Inc.

Page 1 of 7

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
BioTime, Inc. S.S. OR 21,747,569 0 21,747,569 0 44.4%

Page 1 of 7 – SEC Filing

 

 

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

WASHINGTON,
D.C. 20549

 

 

SCHEDULE
13D

 

Under
the Securities Exchange Act of 1934

 

(Amendment
No. 5)

 

ASTERIAS
BIOTHERAPEUTICS, INC.

(Name
of Issuer)

 

Series
A Common Stock, par value $0.0001 per share
  04624N
107
(Title
of class of securities)
  (CUSIP
number)

 

Russell
Skibsted

Chief
Financial Officer

BioTime,
Inc.

1010
Atlantic Avenue

Suite
102

Alameda,
California 94501

(510)
521-3390

(Name,
address and telephone number of person authorized to receive notices and communications)

 

March
28, 2017

(Date
of event which requires filing of this statement)

 

If
the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule
13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [  ].

 

Note:
When filing this statement in paper format, six copies of this statement, including exhibits, should be filed with the Commission.
See Rule 13d-1(a) for other parties to whom copies are to be sent.

 

(Continued
on following page(s))

 

 

Follow Asterias Biotherapeutics Inc.
Trade (AST) Now!
Page 1 of 7